Business
Mirador acquires global rights to Kira's anti-C5a program in pre-merger deal
Mirador Therapeutics, Inc. (San Diego-based) has entered an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting...
REGENXBIO raises USD 100m amid pivotal year for gene therapy pipeline
Rockville, Maryland-based REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering of common stock, intending to raise $100 million...
Mission Therapeutics divests MTX652 to Dimerix for USD 292m, pivots to CNS pipeline
Mission Therapeutics has divested MTX652, a Phase II-ready selective inhibitor of the mitochondrial enzyme USP30, to Australia-based Dimerix Limited (ASX:...
Argenx taps Chai Discovery's AI for de novo antibody engineering in immunology
San Francisco-based Chai Discovery has entered a collaboration agreement with argenx (Euronext & Nasdaq: ARGX) granting the immunology company early access...
Cardiff Oncology raises USD 10m ahead of regulatory push for onvansertib in RAS-mutated colorectal cancer
San Diego-based Cardiff Oncology, Inc. (Nasdaq: CRDF) announced a USD 10 million registered direct offering on July 15, 2026, with proceeds directed toward...
Angelini closes Catalyst Pharma buy for USD 4.1b, gains US foothold in rare neuromuscular disease
Angelini Pharma S.p.A. has completed its acquisition of Coral Gables, Florida-based Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) in a transaction valued at...
Hemispheric emerges from stealth to launch Descartes neuroAI brain decoding model
Israel-based Hemispheric has emerged from stealth with USD 52 million in early-stage funding to commercialize a large-scale AI platform designed to generate...
Lilly bets USD 3.8b on psychedelic medicine with AtaiBeckley acquisition
Eli Lilly and Company (NYSE: LLY) has agreed to acquire AtaiBeckley Inc. (Nasdaq: ATAI), a clinical-stage biotechnology company developing...
United Labs collects USD 13.5m milestone as Novo Nordisk advances UBT251 into Phase II
The United Laboratories International Holdings Limited (HKEX: 03933) has received a USD 13.5 million milestone payment from Novo Nordisk, triggered by the...
Braveheart Bio files for Nasdaq IPO to fund Phase III cardiac myosin inhibitor in HCM
Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage cardiovascular company seeking to enter a hypertrophic cardiomyopathy (HCM) market already served by...
Attovia Therapeutics launches IPO backed by USD 255.8m in nanobody platform funding
Attovia Therapeutics Inc (Nasdaq: ATTO), a clinical-stage immunology company whose nanobody-based biologics platform has attracted USD 255.8 million in...
AdvanCell secures USD 315m to advance Lead-212 alpha therapy into Phase III study
AdvanCell, a clinical-stage radiopharmaceutical company with dual headquarters in Andover, Massachusetts and Brisbane, Australia, has closed an...
Summit divests ridinilazole as oncology strategy takes center stage
Summit Therapeutics (Nasdaq: SMMT) has agreed to sell ridinilazole, a narrow-spectrum antibiotic that completed Phase III development for Clostridioides...
Ligand doubles royalty portfolio to 200 assets with USD 739 million XOMA Royalty acquisition
Ligand Pharmaceuticals (Nasdaq: LGND) has completed its acquisition of XOMA Royalty Corporation for USD 739 million in cash, more than doubling its royalty...
Lōkahi goes public through Glucotrack merger, controls combined company with 90% stake
Lōkahi Therapeutics has completed its strategic business combination with Rutherford, New Jersey-based Glucotrack, Inc. (Nasdaq: GCTK), establishing a...
The AllSci Brief
Systematic R&D and deal news. Daily.